Premium
Transfusion‐related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008
Author(s) -
Ozier Yves,
Muller JeanYves,
Mertes PaulMichel,
Renaudier Philippe,
Aguilon Philippe,
Canivet Nathalie,
Fabrigli Patrick,
Rebibo Danielle,
Tazerout Mahdi,
Trophilme Catherine,
Willaert Béatrice,
Caldani Cyril
Publication year - 2011
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2011.03073.x
Subject(s) - medicine , transfusion related acute lung injury , incidence (geometry) , apheresis , intensive care medicine , fresh frozen plasma , serology , covid-19 , blood transfusion , blood product , emergency medicine , platelet , disease , antibody , surgery , lung , immunology , pulmonary edema , infectious disease (medical specialty) , physics , optics
BACKGROUND: Transfusion‐related acute lung injury (TRALI) is a major cause of transfusion‐related mortality and morbidity. Epidemiologic studies using data from national transfusion schemes can help achieve a better understanding of TRALI incidence. STUDY DESIGN AND METHODS: A multidisciplinary working group analyzed TRALI cases extracted from the French Hemovigilance Network Database (2007‐2008). All notified cases were reviewed for diagnosis. Those meeting the Canadian Consensus Conference criteria for TRALI were classified according to imputability to transfusion and clinical severity. Patient data (clinical characteristics, number and types of products transfused, and serology results) were obtained. RESULTS: There were 62 TRALI cases and 23 possible TRALI cases during the 2‐year period. An immune‐mediated mechanism was identified in 30 of 50 TRALI cases with complete serology. TRALI was considered to be the cause of death in 7.1% of patients and might have contributed to death in an additional 9.4% of TRALI or possible TRALI patients. Occurrence ranked high in obstetrics (15%), after surgery (34%), and in hematologic malignancies (21%). Single‐donor high‐plasma‐volume components were involved in half of the cases where the implicated blood product could be determined and carried the highest risk per component (1:31,000 for single‐donor fresh‐frozen plasma units and apheresis platelet [PLT] concentrates, and 1:173,000 for red blood cells). No incident could be definitively related to the transfusion of solvent/detergent‐treated pooled plasma (>200,000 units transfused), nor to pooled PLT concentrates. CONCLUSION: The proportion of TRALI cases related to plasma‐rich components was lower than previously described.